Google backs $27M launch round for Holy Grail R&D work on two targets: a cancer vaccine and a universal flu jab
Vaccitech isn’t just going after one of the Holy Grails in biotech R&D. It’s taking aim at two of them.
A spinout from some leading …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
